2) The NS demonstrates synergistic anti‐tumor effects by combining PIT with the release of immune checkpoint inhibitors, not only enhancing tumor cell killing but also promoting a robust immune response by downregulating PD‐L1 expression, thereby reducing immune tolerance. This evidence concerns the gene CD274 and neoplasm.